Skip to Content

Truist Financial Corp. acquires new Exelixis, Inc. stock (NASDAQ:EXEL)

Truist Financial Corp. acquires new Exelixis, Inc. stock (NASDAQ:EXEL)

The most recent disclosure that Trust Financial Corp. made with the Securities and Exchange Commission was a 13F. In that filing, the company stated that during the third quarter, it invested in Exelixis, Inc. (NASDAQ: EXEL). The investment fund purchased a total of 92,914 shares of stock in the biotechnology company at approximately $1,456,000.

During the past few months, there have been several other institutional buyers and sellers of EXEL shares. These buyers and sellers have included a wide variety of companies. Natixis Advisors L.P. spent approximately 325,000 dollars over the first three months of 2018 to acquire a new investment in Exelixis. The value of BlackRock Inc.’s holdings in Exelixis increased by 1.9% during the first three months of 2018. BlackRock Inc. now has a total of 32,884,561 shares of the biotechnology company’s stock, which are worth a combined total of $745,493,000 after purchasing an additional 607,183 shares during the most recent period. This brings BlackRock Inc.’s total number of shares to 32,884,561. During the first three months of 2018, the Great West Life Assurance Company of Canada increased the total number of shares of Exelixis that are owned by 7.5%. Great West Life Assurance Company of Canada now has 17,286 shares of the stock held by the biotechnology company following the acquisition of an additional 11,941 shares during the period. The stock is currently valued at $3,900,000 at this time. Yousif Capital Management LLC bought an additional 1.2% of Exelixis common stock over the first three months of 2018, bringing the total percentage of the company’s shares it owned to 32.4%. Yousif Capital Management LLC now has 166,497 shares of the biotechnology company’s stock, which has a current value of $3,774,000 after purchasing an additional 1,931 shares during the period in question. Exelixis received a total investment of $12,872,000 from LSV Asset Management during the year’s first three months. This brings us to the conclusion of our discussion. Institutional investors and hedge funds currently own 84.74% of the company’s stock.

Regarding the stock, a great number of analysts who specialize in equity research have published articles. Cowen announced that they would be decreasing their price objective for Exelixis shares from $26.00 to $21.00 in a research report that was published on November 2. According to a research note published on Monday, January 9, Cowen stated that they would be lowering their price target on Exelixis shares from $21.00 to $20.00. This price target reduction took place. In a research report published on November 2, Morgan Stanley lowered their price target on Exelixis shares from $23.00 to $22.00 while maintaining their “equal weight” rating on the company’s stock. In a research note published on November 2, the Royal Bank of Canada lowered its price objective on Exelixis stock from $31.00 to $29.00. It lowered the “outperform” rating they had previously assigned to the company’s shares. JMP Securities lowered their price objective on Exelixis shares from $26.00 to $25.00 in a research note published on Friday, December 9. Despite this change, their rating for the company remained unchanged at “market outperform.” Eight financial analysts have suggested that investors purchase the stock, while only one has suggested that investors maintain their current holdings. The stock is currently rated as having a consensus recommendation of “Moderate Buy,” and the price target has a consensus value of $27.55, as shown by data provided by Bloomberg.

On December 15, another pertinent piece of information was that Executive Vice President Peter Lamb sold 20,000 of the company’s shares. It was determined that each share was sold at an average price of $15.88, which led to a total sale volume of $317,600.00. The price at which each share was sold was determined. The executive vice president holds a direct ownership stake in the company that is equal to 410,958 shares and is currently valued at $6,526,013.04. Follow the link, which will take you to a filing submitted to the Securities and Exchange Commission. You will have the opportunity to acquire additional information regarding the transaction. In related news, Exelixis director George Poste completed the transaction to sell 40,000 shares of the company’s equity on November 29. This is one of the latest developments about the company. A total of 667,200 dollars worth of shares changed hands on the market, and the average price paid for each share was $16.68. The director is now the owner of 193,189 shares, which have a total value of $3,222,392.52; the company previously owned these shares. Information regarding the sale submitted to the Securities and Exchange Commission can currently be accessed online through the SEC’s website. On Thursday, December 15, Executive Vice President Peter Lamb also put 20,000 of the company’s shares up for sale by exercising an option he had. The sale of the shares generated a total gross profit of $317,600.00, with the price of each share averaging $15.88. As a direct result of the sale, the executive vice president now owns 410,958 shares. Based on the current market price, these shares are worth $6,526,013.04. Disclosures that are related to the sale might be found in this section of the website. The current percentage of the company’s shares held by company insiders is 2.90 percent.

EXEL was first available for trading on Thursday at $16.30. The stock’s market capitalization of $5.26 billion can be broken down as follows: it has a price-to-earnings ratio of 0.55, a price-to-earnings-to-growth ratio of 0.55, and a beta value of 0.69. The moving averages for the company currently stand at $16.46 for the last fifty days and $17.70 for the last 200 days. These figures were most recently found in the company’s financial statements. Exelixis Inc.’s share price fluctuates throughout the year, typically within a range that extends from $14.87 to $23.40.

On November 1, Exelixis announced the publication of its most recent quarterly earnings report, which can be located on the company’s website under the ticker symbol “EXEL.” The biotechnology company reported an earnings per share (EPS) figure for the quarter that came in at $0.23, which was $0.05 higher than the estimated floating around the industry, which was $0.18. The sales for the company during the quarter came in significantly higher than the $404.14 million that the analysts predicted, coming in instead at $411.74 millionbol “EXEL.” The biotechnology company reported an earnings per share (EPS) figure for the quarter that came in at $0.23, which was $0.05 higher than the estimated floating around the industry, which was $0.18. The sales for the company during the quarter came in significantly higher than the $404.14 million that the analysts predicted, coming in instead at $411.74 million. The return on equity for the business came in at 13.11 percent, while the net margin it achieved was 18.78 percent. According to projections made by analysts who specialize in equity research, Exelixis, Inc. is projected to generate earnings of $0.53 per share during the current fiscal year.

The biopharmaceutical company Exelixis, Inc. focuses on developing, marketing, and researching novel anti-cancer medications. COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO are some of the brand names associated with the products that can be purchased today. It is believed that Stelios B. Goodman and his brother, Corey S. Goodman, were responsible for the establishment of the business.

Tags

Leave a comment

Your email address will not be published. Required fields are marked *